September 10 - 12, 2020
 
Registration Deadline: November 25, 2020
Virtual Platform Close Date: December 10, 2020

CME/CE Credit

THIS CONFERENCE IS FOR YOU

Rheumatologists • Internists • Family Physicians • Physician Assistants • Nurse Practitioners • Nurses • Pharmacists

 

Learning Objectives

After completing this live activity, participants should be better able to:

Special Issues in the Management of Autoimmune Diseases

  • Explain the historical and contemporary role of placebos in medicine.
  • Describe the prevention and treatment of infections associated with biologics and other immunosuppressive therapies.
  • Review the pharmacokinetic effects of anti-drug antibodies when utilizing biologic therapies.
  • Discuss the safety of immune checkpoint inhibitors in patients with autoimmune diseases.
  • Outline current vaccination recommendations in patients with rheumatic diseases.
  • Discuss the signs and symptoms suggestive of developing early arthritis.
  • Evaluate current clinical evidence on the efficacy and safety of cannabinoid therapy in rheumatic disease pain management.

Rheumatoid Arthritis (RA)

  • Outline the roles of current and emerging therapies for RA including immunosuppressive, anti-inflammatory, and disease-modifying therapies for individualized treatment plans.
  • Evaluate emerging data on pathophysiology and predictive biomarkers for early identification of RA.

Osteoarthritis (OA)

  • Discuss the role of interventional therapies for knee osteoarthritis.
  • Review current guidelines for the management of osteoarthritis.

Scleroderma

  • Review current diagnosis and treatment strategies for the various manifestations of localized and systemic scleroderma.

Systemic Lupus Erythematosus (SLE)

  • Explain antinuclear antibodies testing to diagnose systemic lupus erythematosus (SLE).
  • Recognize the clinical presentation of thrombotic microangiopathy (TMA) and atypical hemolytic uremic syndrome (aHUS) in patients with lupus.
  • Review the efficacy and safety data on new treatment options for SLE.

Systemic Vasculitis

  • Recognize systemic vasculitis and develop a plan for treatment.

Severe Raynaud’s Disease

  • Evaluate therapeutic options for the management of Raynaud’s disease.

Myositis

  • Describe how myositis-specific autoantibodies define different types and subtypes of inflammatory myopathies.
  • Review current American College of Rheumatology (ACR) vasculitis guidelines.

Spondylarthritis

  • Integrate imaging options to aid in the diagnosis of axial spondylarthritis and develop an evidence-based therapy plan for patients.

Psoriatic Arthritis

  • Outline evidence-based choices for initial and second line therapies in psoriatic arthritis.

Autoimmune Skin Diseases

  • Develop a strategy for identifying and managing cutaneous adverse reactions.

Gout

  • Review emerging gout guidelines and their implications in clinical practice.

Complex Cases: Interstitial Lung Disease in RA, Renal Disease, Decreased Bone Mass (osteoporosis)

  • Evaluate strategies to diagnose and manage patients with renal disease and decreased bone mass.
  • Initiate a management plan for patients on bisphosphonate therapy while balancing the efficacy and adverse effects of treatment.
  • Outline a treatment plan for interstitial lung disease in patients with rheumatic diseases.

 

Accreditation and Designation statements
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
September 10, 2020 – September 12, 2020 - The Postgraduate Institute for Medicine designates this live activity for a maximum of 17.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
September 15, 2020 – December 30, 2020 - The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 17.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this knowledge based continuing education activity for 17.0 contact hours (1.7 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2199-L01-P
Type of Activity (select one): Knowledge

Hardware/Software Requirements
Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity. 

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 17.0 contact hours. Pharmacotherapy contact for Advance Practice Registered Nurses will be indicated on your certificate.

 

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 17.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 17.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

 

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

 

 

    Follow Us

    Jointly Provided By

    In Association With